Based on this hypothesis, additional experiments have suggested that a combination of rapalogs (Rapamycin and its analogs) and angiogenesis inhibitors, such as everolimus plus sorafenib, may significantly decrease the tumor size and improve the therapeutic efficacy by inhibiting mTORC1 and the mitogen-activated protein kinase (MAPK) pathway (Yang et al., 2017), which is superior to the treatment with single rapalogs alone. This evidence concerns the gene WNK2 and neoplasm.